Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOBERMANN: Dobutamine and Tocilizumab in High-Risk AMI
NCT05350592Phase 2Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dobutamine, tocilizumab in acute myocardial infarction (AMI), sponsored by Rigshospitalet. Started Mar 2022; status: active, not recruiting.
02
Drugs
dobutaminetocilizumab
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT05350592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350592.